Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

University of Toronto

$17,500.00

Precision medicine in prostate cancer: the role of somatic tissue testing in delivering personalized cancer care

FY 2023-24

Summary
Prostate cancer is the most common cancer among men and the second leading cause of cancer-related deaths. An estimated 20-30% of prostate cancer patients have a mutation in DNA damage repair genes, 50% of which are heritable and can affect family members and the other 50% are non-heritable. Research suggests that mutated prostate cancer responds well to targeted drugs, thus highlighting the importance of testing to identify those patients. In 2021, Ontario funding allowed medical doctors to order genetic tests to identify heritable mutations. While there is also funding to test for non-heritable mutations, it is not being done routinely for various reasons that remain unclear. The aim of our project is to investigate the barriers to and impact of testing for non-heritable mutations on patients and the healthcare system. At the Sunnybrook Odette Cancer Centre, approximately 1500 prostate cancer patients are seen each year, making our centre one of the highest volume centres in Canada. Non-heritable genetic testing is done directly on the tumor using an in-house panel which includes 161 genes, many of which have significant implications on patient outcomes. Ontario provincial funding currently allows for reporting on only 4 of the 161 genes. We will analyze tumor samples and investigate the cost of reporting on the full 161 genes and will report the prevalence of mutations in these genes and the impact that testing had on patient outcomes. We will also explore barriers to and limitations of testing. With precision oncology occupying an increasing role in delivering personalized cancer treatment, we hope that our project will establish local guidelines for tumor testing to ultimately make comprehensive genetic testing part of every prostate cancer patient's care plan.
Program
Master's Award: Canada Graduate Scholarships
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
506092
Name
Hanna Lilian
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Precision medicine in prostate cancer: the role of somatic tissue testing in delivering personalized cancer care
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Advanced Prostate Cancer; Cancer Genetics; Next-Generation Sequencing; Novel Cancer Therapeutics; Parp Inhibitors; Precision Medicine
Abstract
Prostate cancer is the most common cancer among men and the second leading cause of cancer-related deaths. An estimated 20-30% of prostate cancer patients have a mutation in DNA damage repair genes, 50% of which are heritable and can affect family members and the other 50% are non-heritable. Research suggests that mutated prostate cancer responds well to targeted drugs, thus highlighting the importance of testing to identify those patients. In 2021, Ontario funding allowed medical doctors to order genetic tests to identify heritable mutations. While there is also funding to test for non-heritable mutations, it is not being done routinely for various reasons that remain unclear. The aim of our project is to investigate the barriers to and impact of testing for non-heritable mutations on patients and the healthcare system. At the Sunnybrook Odette Cancer Centre, approximately 1500 prostate cancer patients are seen each year, making our centre one of the highest volume centres in Canada. Non-heritable genetic testing is done directly on the tumor using an in-house panel which includes 161 genes, many of which have significant implications on patient outcomes. Ontario provincial funding currently allows for reporting on only 4 of the 161 genes. We will analyze tumor samples and investigate the cost of reporting on the full 161 genes and will report the prevalence of mutations in these genes and the impact that testing had on patient outcomes. We will also explore barriers to and limitations of testing. With precision oncology occupying an increasing role in delivering personalized cancer treatment, we hope that our project will establish local guidelines for tumor testing to ultimately make comprehensive genetic testing part of every prostate cancer patient's care plan.
Competitiondate
202312
Approvedterm2
1 yr 0 mth
Pinamesdelim
Hanna, Lilian
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~